Monday, March 17, 2025 8:42:09 AM
Good to read your thoughts on the upcoming approval decision; I believe most people here feel as you do, that DCVax will be approved.
"nothing will change on approval"
Now about your latest comment: "Better ways to charity than flushing your money in[to] NWBO [an] inept crew." Seems a bit over the top.
NWBO is the first company in +20 years to have a successful GBM trial, the last +300 trials failed. That's quite an accomplishment, for any biotech business, especially a startup pre-revenue biotech. The fact that they stayed the course over the many years this trial has taken, to obtain indisputable evidence of long-term efficacy, whilst battling Wall Street forces intent on their destruction, speaks volumes to the ability of this "crew". I'm not aware of any other company having a treatment platform on the cusp of approval that many feel will be applicable to most solid tumor cancers. The Roswell cancer institute has entrusted their dendritic cell portfolio to NWBO for Devlopment.
The market research group Delve Insight has DCVax as the #1 treatment for GBM through 2030. (https://www.delveinsight.com/report-store/dcvax-l-emerging-drug-insight-and-market-forecast).
Not sure why you are here, other than the obvious.
__________________________________________________
Not to be taken as investment advice - Do your own due diligence.
"nothing will change on approval"
Now about your latest comment: "Better ways to charity than flushing your money in[to] NWBO [an] inept crew." Seems a bit over the top.
NWBO is the first company in +20 years to have a successful GBM trial, the last +300 trials failed. That's quite an accomplishment, for any biotech business, especially a startup pre-revenue biotech. The fact that they stayed the course over the many years this trial has taken, to obtain indisputable evidence of long-term efficacy, whilst battling Wall Street forces intent on their destruction, speaks volumes to the ability of this "crew". I'm not aware of any other company having a treatment platform on the cusp of approval that many feel will be applicable to most solid tumor cancers. The Roswell cancer institute has entrusted their dendritic cell portfolio to NWBO for Devlopment.
The market research group Delve Insight has DCVax as the #1 treatment for GBM through 2030. (https://www.delveinsight.com/report-store/dcvax-l-emerging-drug-insight-and-market-forecast).
Not sure why you are here, other than the obvious.
__________________________________________________
Not to be taken as investment advice - Do your own due diligence.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
